The SURPASS-2 trial compared three doses of tirzepatide (5 mg, 10 mg, 15 mg) with semaglutide 1 mg, in adults with type 2 diabetes who were already taking metformin. Tirzepatide produced greater HbA1c reductions than semaglutide, with decreases of 2.1% to 2.5% depending on dose, compared to 1.9% with semaglutide. 1,2,3In terms of safety, tirzepatide had a similar gastrointestinal side-effect profile to semaglutide, with nausea and other GI symptoms being the most common. 2 Overall, tirzepatide provided superior glycemic control and more pronounced weight reduction compared to semaglutide, while maintaining a comparable safety and tolerability profile. Patients on the 15 mg dose experienced an average weight loss of 12.4 kg, compared to 6.2 kg in those taking semaglutide.